Opinion: STAT+: The real work for making dramatic gains against pancreatic cancer is just beginning

An international study co-led by a UCLA research team reported on May 31 at the American Society of Clinical Oncology (ASCO) meeting in Chicago that patients with pancreatic cancer who received the drug daraxonrasib lived for an average of 13.2 months. This represents a substantial increase compared to the 6.6 to 6.7 months experienced by patients treated with chemotherapy alone. In anticipation of these findings, the U.S. Food and Drug Administration (FDA) granted early access to daraxonrasib a month prior to the meeting for select patients who had not responded to existing treatments for pancreatic cancer. The significant media attention surrounding this expedited drug access underscores the persistent public and scientific interest in developing treatments that can significantly improve survival rates for complex and heterogeneous cancers. The study highlights the challenges in treating such malignancies, particularly when relying on single-drug therapies to achieve better clinical outcomes. The research suggests that advancements in treating pancreatic cancer are ongoing, with daraxonrasib showing promising results in extending patient survival.